FDA PMR/PMC 市販後義務・約束試験と AI 支援

FDA Post-marketing Requirements（PMR、市販後義務試験）・Post-marketing Commitments（PMC、市販後約束試験）は、FDA 承認済医薬品・生物製剤に対し Safety・Efficacy・Clinical Pharmacology・Nonclinical Toxicology の市販後試験を課す制度で、FDAAA（Food and Drug Administration Amendments Act of 2007）Section 901（2008-03-25 施行）が法的根拠。FDA 公式 PMR/PMC Introduction ページ（FDA PMR/PMC Introduction）・Searchable Database（FDA PMR/PMC Searchable Database）・FAQ（FDA PMR/PMC FAQ）で公開運用。定義差：PMR は Statute/Regulation 基盤で Sponsor 必須義務、PMC は Sponsor 任意合意。Federal Register 2025-05-30 公布（FDA Federal Register PMR/PMC Report 2025-05-30）で FY2023 年次報告・FY2023-09-30 時点 Status 集計公表。FDAAA Section 505(o)(3)(E)(ii) で Applicant に Periodic Status Report 義務、21 CFR 314.81(b)(2)(vii) Annual Report での Substitute 可能。PMR Trigger：①Known Serious Risk 評価、②Signal of Serious Risk 評価、③Unexpected Serious Risk 同定。PMC は Sponsor 自主・Accelerated Approval の Confirmatory Trial・Pediatric Study 等。Accelerated Approval PMR（Oncology 等）は FDORA 2022 で強化され 7 Year Limit + Progress Tracking 必須。Status：Pending・Ongoing・Delayed・Fulfilled・Released・Terminated の 6 カテゴリ。CBER SOPP 8413（PMC）・SOPP 8415（PMR）運用手順。PMC PMR Fulfillment 2013-2016 調査（PMC 論文）で Compliance 状況分析。PMC 2024-01 Biostatistics Blog（On Biostatistics PMR vs PMC 2024-01）で差異整理。PREA（Pediatric）PMR 連動、Oncology Accelerated Approval PMR の Specificity 研究（PMC 2024）も進行。本記事では、FDA PMR/PMC の AI 支援を、Trigger 判定・Study Design・Status Tracking・Multi-region 連動の観点で玄人目線で詳述する。

PMR と PMC の定義差

項目	PMR	PMC
法的根拠	Statute/Regulation（FDAAA 505(o)）	Sponsor 任意合意
性質	必須義務	Agreed Commitment
Non-compliance Consequence	Civil Monetary Penalty	通常なし（但し信頼低下）
対象	Safety 中心	Safety・Efficacy・CPK・Toxicology
Trigger 時点	Approval 時・Post-approval	Approval 時・Labeling 変更時
Annual Report	必須（21 CFR 314.81）	必須
Public Database	Searchable	Searchable（506B PMC）

PMR Trigger（FDAAA 505(o)）

• Known Serious Risk Assessment
• Signal of Serious Risk Assessment
• Unexpected Serious Risk Identification
• Risk Evaluation and Mitigation Strategies（REMS）連動
• Accelerated Approval Confirmatory Trial（FDORA 2022 7 Year Limit）
• Pediatric Research Equity Act（PREA）Pediatric Study
• Subpart H（21 CFR 314.500）Accelerated Approval
• Subpart E（21 CFR 601 Subpart E）Biologics Accelerated Approval

Status カテゴリ

Status	意味
Pending	未開始
Ongoing	実施中
Delayed	期限遅延
Submitted	Final Report 提出済
Fulfilled	完了 FDA 受諾
Released	FDA が PMR 解除
Terminated	Sponsor 撤回等

AI 支援の 8 領域

1. PMR/PMC 適格性判定

Drug Profile・Risk Signal から PMR/PMC 類型を AI で判定。Trigger 条件評価。

2. Study Design 最適化

Post-marketing Study Design を AI で設計。RCT・PASS・Registry・RWD 選択。

3. Timeline Tracking

Milestone（Protocol Submission・Interim Analysis・Final Report）を AI で監視。Delay Prevention。

4. Accelerated Approval Confirmatory

FDORA 2022 7 Year Limit 対応 Confirmatory Trial を AI で加速。

5. Pediatric PMR（PREA）連動

PREA 対応 Pediatric PMR を AI で統合管理。Timeline Harmonization。

6. Annual Report 作成

21 CFR 314.81(b)(2)(vii) Annual Report を AI でドラフト。Status Update。

7. Multi-region Post-marketing

FDA PMR/PMC + EMA PASS/Specific Obligation + PMDA 再審査・使用成績調査 + NMPA 上市后要求を AI で統合。

8. REMS 連動

REMS Assessment・ETASU（Elements to Assure Safe Use）の PMR 位置付けを AI で管理。

Accelerated Approval PMR の FDORA 2022 改革

• Accelerated Approval の Confirmatory Trial 強化
• 7 Year Limit（FDORA 2022 Section 3210）
• Progress Report 6 か月毎
• Withdrawal Procedures 簡素化
• Pre-approval Enrollment Evidence
• Oncology Confirmatory Trial 特化
• Continued Approval Condition
• FDA Expedited Withdrawal Authority

AI パイプライン

1. Step 1: Approval 時の PMR/PMC 設定
2. Step 2: Protocol Development
3. Step 3: FDA Protocol Submission
4. Step 4: Study Initiation
5. Step 5: Interim Analysis + Annual Report
6. Step 6: Safety Signal Monitoring
7. Step 7: Final Study Report
8. Step 8: FDA Fulfillment 審査
9. Step 9: Fulfilled or Released
10. Step 10: Label Update（必要時）

Multi-region Post-marketing 対比

地域	制度
FDA	PMR（FDAAA 505(o)）+ PMC + 506B
EMA	Post-Authorisation Safety Study（PASS）+ Specific Obligation
PMDA	再審査・再評価・使用成績調査（GVP 省令）
NMPA	上市后要求・药物警戒
MHRA	Post-authorisation Study
Health Canada	Post-approval Commitment
TGA	Post-market Study

失敗パターンと回避策

落とし穴1：PMR 期限遅延

Delayed Status で FDA Enforcement Risk。AI で Milestone Tracking。

落とし穴2：Annual Report 不備

21 CFR 314.81(b)(2)(vii) 要素欠落で FDA 不受諾。AI で Template 完全化。

落とし穴3：Accelerated Approval Confirmatory 遅延

FDORA 2022 7 Year Limit 超過で Withdrawal Risk。AI で Timeline 優先管理。

落とし穴4：Multi-region 不整合

FDA PMR + EMA PASS + PMDA 使用成績調査を別々 Design で非効率。AI で Global Protocol。

落とし穴5：REMS 連動欠如

ETASU の PMR 性質未認識で要件抜け。AI で統合管理。

KPI 設計の観点

• PMR/PMC Timely Completion
• Fulfilled 率
• Delayed 率低減
• Annual Report 品質
• Accelerated Approval Confirmatory 7 Year 内達成
• Multi-region 整合
• REMS Assessment 品質

まとめ：FDA PMR/PMC AI 支援の設計指針

1. FDAAA 2007 Section 901 基盤・2008-03-25 施行
2. PMR（必須義務）vs PMC（任意合意）の差別化
3. PMR Trigger 3 類型（Known Risk・Signal・Unexpected Risk）
4. Status 6 カテゴリ（Pending・Ongoing・Delayed・Submitted・Fulfilled・Released・Terminated）
5. FDORA 2022 Accelerated Approval Confirmatory 7 Year Limit
6. PREA Pediatric PMR・Subpart H/E Accelerated Approval 連動
7. 21 CFR 314.81(b)(2)(vii) Annual Report
8. CBER SOPP 8413（PMC）・SOPP 8415（PMR）運用
9. FDA Federal Register 2025-05-30 FY2023 年次報告公布
10. AI は 判定・Design・Tracking・Confirmatory・Annual Report・Multi-region・REMS、最終判断は Regulatory・Medical・Biostat・Pharmacovigilance

FDA PMR/PMC は FDAAA 2007 + 2008 施行の市販後試験制度で、PMR（Statute/Regulation 必須）vs PMC（Sponsor 任意合意）の差別化、FDORA 2022 で Accelerated Approval Confirmatory 7 Year Limit 強化、Federal Register 2025-05-30 FY2023 年次報告公布。AI による PMR/PMC 判定・Study Design・Timeline Tracking・Annual Report・Accelerated Approval Confirmatory・Multi-region 整合・REMS 連動で市販後 Compliance 効率化。判断の人間主導と反復的 PMR 戦略・Multi-region Harmonization の AI 自動化が、グローバル医薬品市販後管理の競争力を決定づける。

renue独自視点：FDA PMR/PMC AI支援の3つの落とし穴

renue社はPV/GMP/品質/臨床試験/AI創薬/BMV/Drug Shortage/RWD/IDMP/PPS/DHCPL/SaMD/DDI/Controlled Substance/AMR/SSDC/PGx/ERA/Packaging/BE/WHO PQ/Project Orbis/QT-QTc/RTOR/EU QP/PREA/PRV/S1B(R1)/BTD/Fast Track/EUA/S9/M12/CGT/S6(R1)/IRA/S5(R3)/340B/ACCESS/S7A-S7B/PMDA Reliance領域で86本（A088-A173）のシリーズを蓄積し、FDA PMR/PMCがA161 BTD・A162 Fast Track・A156 RTOR・A154 Project Orbis・A163 EUA・A159 PRV・A158 PREA/RACE Act（Accelerated Approval Confirmatory Trial義務）・A140 OMOP CDM RWE・A112 PV Signal・A135 CCDS・A143 DHCPL・A144 SaMD PCCP・A152 ICH M13A BE Post-approval・A166 CGT Designation・A168 IRA Medicare（PMR Status連動）・A173 PMDA GPSP/DBS/J-DOEと交差する「Accelerated Approval Lifecycle × Regulatory Science Continuation」核心と認識している。本稿ではFDA PMR/PMC AI支援で汎用LLMが届かない3落とし穴を、一次資料（FDA PMR/PMC Official・Federal Register FY2023 Report 2025-05-30・FDA PMR/PMC Guidance for Industry・PMC 2024 Companion Diagnostics PMR FDA/EMA/PMDA/MFDS）を参照し整理する。

落とし穴① PMR vs PMC区分判定・Statute/Regulation基盤・Confirmatory Trial義務・FDORA 2022 Accelerated Approval 7-Year Limitの「Trigger×Enforcement Risk精度」

FDA PMR/PMC基準は①PMR（Statute Requirement）＝FDCA 505(o)(3) Safety/Effectiveness懸念時・FDCA 505-1 REMS義務・Accelerated Approval Subpart H 21 CFR 314.510/601.41 Confirmatory Trial義務・Pediatric Research Equity Act PREA 義務・Animal Rule 21 CFR 314.610等、②PMC（Sponsor Agreement）＝Voluntary Commitment、③FDORA 2022（Food and Drug Omnibus Reform Act 2022-12-29）でAccelerated Approval Confirmatory Trial 7年上限強化・Withdrawal Process明確化、④FY2023年次報告（Federal Register 2025-05-30公布）で企業Performance集計、⑤Annual Status Report 60日以内提出義務、⑥公開Website四半期更新、⑦Status Category（Not Yet Due・Fulfilled・Released・Delayed・Pending・Submitted・Terminated・Ongoing）、⑧Failure to Conduct PMR →FDCA違反Enforcement Action（PMC不該当）の差（FDA PMR/PMC）。汎用LLMに「PMR/PMC判定戦略を」と頼むと概念説明は出るが、①PMR自動Trigger判定（Safety/Effectiveness Signal・Subpopulation Efficacy不足・Manufacturing Quality懸念）、②REMS-required PMR vs Non-REMS PMR区別、③A161 BTD/A162 Fast Track/A156 RTOR/A154 Orbis承認時のPMR Probability Forecast、④Accelerated Approval Subpart H/E 別Pathway PMR要件差、⑤A163 EUA特有 Confirmatory Trial要件（COVID-19 Vaccines Comirnaty/Spikevax Full Approval移行事例）、⑥A158 PREA Pediatric Study PMR vs Waiver/Deferral判定、⑦A164 ICH S9 Oncology承認時のPMR頻発パターン・Project FrontRunner連動、⑧A168 IRA Medicare Selected Drug判定時のPMR Status連動影響、⑨Pediatric Exclusivity 6か月延長 PREA PMR連動戦略、⑩FDORA 2022 Accelerated Approval 7-Year Confirmatory Trial Expedited Withdrawal Process（WeLReQ・Intervening Withdrawal Procedure・Expedited Withdrawal Procedure）、⑪Withdrawal事例学習（2021-2024 Oncology Makena/Melphalan flufenamide/Idelalisib/Oxbryta/Lapatinib等）、⑫Pre-Approval PMR Commitment Negotiation戦略（Advisory Committee・AIP Agreement in Principle）、⑬Clinical Endpoint vs Surrogate Endpoint Confirmatory Trial選定、⑭Patient Recruitment Challenge（新規治療普及後Placebo Group困難）、⑮Single Arm vs Randomized Trial Design、⑯Basket/Umbrella/Master Protocol活用、⑰A140 OMOP CDM RWE Real-world Confirmatory Evidence可能性、⑱A142 PPS Patient Preference活用Benefit-Risk更新、⑲A115 ICH E6(R3)・A148 SSDC・A169 S5(R3) DART Post-approval連動、⑳Pediatric Rare Disease A159 PRV連動、㉑Manufacturing Site Transfer PMR・A151 ISO 15378・A110 Annex 1 CCS連動、㉒A145 ICH M12 DDI Post-approval・A155 E14 C-QTc Post-approval・A160 S1B(R1) WoE・A172 S7 Safety Pharm連動、㉓Pediatric DDI PK Study PMR PEPFAR事例、㉔PMC Categorization（Additional Safety・Efficacy in Subpopulation・Formulation/Route Change・CMC・Manufacturing Process）、㉕A99/A112/A135/A143 Post-approval Signal連動、㉖Annual Status Report Quality（Non-compliance + 60日遅延リスク）、㉗FDA Advisory Committee Post-approval ODAC/DDAC/CTGTAC連動、㉘A166 CGT Designation Generic Post-approval連動、㉙A152 ICH M13A BE SUPAC Variation連動、㉚Regulatory Cluster Oncology/Cardiovascular/CNS/Neurology別Expectations、㉛CEO/CFO Investor Relations PMR Disclosure 10-Q/10-K記載、㉜Post-approval Development Resource Allocationをリスク管理。対策は、①PMR/PMC Auto-Classifier（FDCA 505(o)(3)/PREA/REMS/Subpart H/Animal Rule × Trigger Signal）、②FDORA 2022 Expedited Withdrawal Risk Simulator、③Annual Status Report 60日Deadline Tracker + Quality Quality Checker、④A161/A162/A156/A154 Expedited Program Post-approval PMR Probability Forecast、⑤A140 RWE Confirmatory Evidence Designer、⑥A142 PPS Benefit-Risk Update、⑦A099/A112/A135/A143 Post-approval Signal連動、⑧A145/A155/A160/A172 Nonclinical Post-approval連動、⑨A151/A110/A141 CMC連動、⑩A158 Pediatric PMR・A159 PRV・A164 Oncology・A167 Biologics・A152 Generic連動、⑪CEO/CFO 10-Q/10-K Disclosure PMR Status、⑫5者合議（Regulatory Affairs・Medical Affairs・Clinical Development・Biostatistician・Pharmacovigilance）＋Post-approval Development Expert＋Advisory Committee Strategist。

落とし穴② Accelerated Approval Confirmatory Trial Design・Patient Recruitment・Withdrawal Risk Management・Single Arm vs RCT選定の「Regulatory Science Continuation精度」

Accelerated Approval Subpart H/Eで承認された医薬品はConfirmatory Trial義務を持ち（FDORA 2022以降7年上限）、Trial失敗時のWithdrawal Risk・Patient Recruitment Challenge・Study Design選定が極めて複雑。2021-2024で複数Oncology Accelerated Approval取消事例（Makena 2023-04・Melphalan flufenamide 2021-10・Idelalisib 2022・Oxbryta 2024・Lapatinib 2024）（FDA Unimproved Enforcement of PMR/PMC）。汎用LLMに「Confirmatory Trial戦略を」と頼むと一般論は出るが、①Single Arm vs Randomized Trial Design選定（患者・Placebo Arm倫理問題）、②Clinical Endpoint vs Surrogate Endpoint（OS vs PFS vs ORR vs MRD）、③ICH E9(R1) Estimand Framework整合（A115連動）、④A148 SSDC Late-stage Limited Safety Collection、⑤A140 OMOP CDM RWE External Control・Real-world Comparative Effectiveness活用、⑥Basket/Umbrella/Master Protocol（A154 Project Orbis連動）、⑦Patient Recruitment Rate予測（Standard of Care変化速度・Competing Trials・Patient Advocacy活動）、⑧Project FrontRunner事前Confirmatory Trial着手（A154/A164連動）、⑨Subpopulation Confirmatory Trial（A149 PGx Genomic Biomarker選定）、⑩A169 S5(R3) DART Pediatric Confirmatory、⑪A158 PREA Pediatric Confirmatory（RACE Act Pediatric Oncology）、⑫A144 SaMD Companion Diagnostic Post-approval Re-qualification、⑬A135 Modality (CGT/ADC/Radioligand/Oligo)別Confirmatory戦略、⑭A112 PV Signal Post-approval Surveillance連動、⑮A135 CCDS Pregnancy/Lactation/Pediatric Statement更新、⑯A143 DHCPL発出Trigger Post-approval、⑰Accelerated Approval 7-Year Limit Timeline Gantt、⑱Withdrawal Process（Intervening Withdrawal vs Expedited Withdrawal vs Sponsor Voluntary Withdrawal）、⑲Advisory Committee ODAC/DDAC 4-0 vs 4-8 vs Split Decision事例、⑳Post-approval Patient Access継続（期間限定Continued Access/Expanded Access）、㉑A168 IRA Medicare 選定時のMFP+PMR Interaction、㉒A170 340B × PMR影響（Specialty Pharmacy Carve-in）、㉓A147 AMR PASTEUR Subscription + PMR連動、㉔A163 EUA→Full Approval移行Confirmatory Trial（Comirnaty 2021-08 Full Approval事例）、㉕A161 BTD承認時のConfirmatory Trial Pre-specification、㉖A159 PRV Rare Pediatric Orphan Confirmatory、㉗Supply Chain Resilience Confirmatory Timeline（A139 Drug Shortage連動）、㉘Orphan Disease小Population Confirmatory、㉙Manufacturing Scale-up Confirmatory連動（A110/A151連動）、㉚CEO/CFO 10-Q/10-K Investor Guidance Confirmatory Timeline、㉛Quarterly Earnings Release Confirmatory Progress Update、㉜Press Release Discipline（Insider Trading Regulation・Simultaneous Global Disclosure）、㉝Patient Advocacy連携（Rare Disease Patient Group継続サポート）、㉞Regulatory Cluster Cardiovascular/Neurology/Hematology/Immunology別Expectations、㉟A133 Radioligand Confirmatory（Radioactive Dosimetry）、㊱A167 Biologics Confirmatory特別（Species Differences考慮）をLLM単独で一貫管理できない。対策は、①Confirmatory Trial Designer（Single Arm vs RCT + Clinical Endpoint vs Surrogate + ICH E9(R1) Estimand + Project FrontRunner連動）、②Patient Recruitment Rate Predictor・SOC Shift Monitor、③Withdrawal Risk Simulator・Accelerated Approval 7-Year Timeline Gantt、④A140 RWE External Control Designer、⑤Basket/Umbrella Master Protocol Generator、⑥A148 SSDC・A115 ICH E6(R3)/E9(R1) Estimand連動、⑦A158 Pediatric/A159 PRV/A164 Oncology/A154 Project Orbis Confirmatory連動、⑧A135 Modality別Confirmatory Strategy、⑨A144 CDx Post-approval Re-qualification、⑩A112/A135/A143 Post-approval Signal Cockpit、⑪A168 IRA/A170 340B × PMR Interaction、⑫A147 AMR PASTEUR + PMR連動、⑬CEO/CFO 10-Q/10-K Disclosure Discipline、⑭6者合議（Regulatory・Medical Affairs・Clinical Development・Biostatistician・Commercial・Patient Advocacy）＋Advisory Committee Strategist＋ODAC/DDAC KOL＋Withdrawal Crisis Management Expert。

落とし穴③ Multi-region Post-approval Study Harmonization（FDA PMR-PMC・EMA Post-authorisation Measures/PASS/PAES・PMDA GPSP/DBS/再審査・NMPA 上市后研究）・RWE・A140 OMOP CDM・A144 SaMD PCCPの「Global Post-market Lifecycle統合」

Multi-region Post-approval整合は①FDA PMR/PMC（FDAAA 2007）、②EMA Post-authorisation Measures（PAM）・Post-authorisation Safety Study（PASS）・Post-authorisation Efficacy Study（PAES）・Category 1/2/3・GVP Module VIII、③PMDA GPSP（Good Post-marketing Study Practice）・Re-examination Period（再審査）・Use-results Survey（使用成績調査）・DBS Database Study（A173 MID-NET連動）・Drug Use Surveillance、④NMPA 上市后研究（2020-08 医薬品上市后研究技術指導原則・A170 2020-09 Pediatric RWD Technical Guidance連動）、⑤Health Canada Notice of Compliance with Conditions NOC/c Commitment、⑥Swissmedic Post-authorisation Condition、⑦TGA Australia Condition of Registration、⑧PMC 2024 Companion Diagnostics PMR FDA/EMA/PMDA/MFDS比較、⑨A144 SaMD PCCP Post-approval Model Drift Monitor、⑩A140 OMOP CDM RWE Multi-region Post-approval Cohort、⑪Six-Year Trends Real-World Data Japan（PMC 2024-06論文）、⑫A142 PPS Patient Preference Post-approval Update、⑬A149 PGx Post-approval Pharmacogenomic RWE、⑭A135 Modality (CGT/ADC/Radioligand/Oligo)別Post-approval Lifecycle、⑮A135 CCDS Multi-region Label Update同期（USPI/SmPC/添付文書/说明书 5極）、⑯A143 DHCPL Multi-region Risk Communication（A112 Signal連動）、⑰A152 ICH M13A BE Part II Post-approval Variation（SUPAC・Manufacturing Site Transfer・Formulation Change）、⑱A166 CGT Designation Generic Post-approval、⑲A147 AMR Antibiotic Resistance Surveillance（PASTEUR Act連動）、⑳A151 ISO 15378 Packaging Post-approval Change、㉑A110 Annex 1 CCS Post-approval、㉒A141 IDMP Post-approval Master Data維持、㉓A150 ERA Post-approval Environmental Monitoring、㉔A099 EudraVigilance Post-approval Signal、㉕A112 PV Signal Detection Disproportionality・A135 CCDS Update Trigger、㉖Re-examination Period（日本Re-examination 4/6/8/10年・Conditional Early Approval 条件外し）、㉗日本 Drug Use Surveillance（MHLW 2005 Ordinance 38以降DBS導入）、㉘PMDA MID-NET 10病院・J-MID・DPC/MID-NET・Medical Data Vision・JMDC等 Japan RWD Ecosystem、㉙PMDA 2023 RWD Guideline Trilogy（Package Insert・RMP Integration・DBS Design）、㉚NMPA 真实世界数据 2020-09 Technical Guidance・药品上市后变更管理办法 2021-01-13、㉛Health Canada RWE Action Plan、㉜Canada Drug Agency Pan-Canadian Post-Market Drug Evaluation Program、㉝TGA Black Triangle Scheme、㉞Swissmedic Post-Marketing Surveillance、㉟韓国MFDS Re-examination・MFDS Enforcement Decree、㊱EMA Risk Management Plan RMP Module VIII連動、㊲A140 Japan MID-NET + OMOP CDM Harmonization戦略、㊳Registry-based Confirmatory Study（A115 ICH E6(R3) + A140 Real-world Registry）、㊴Digital Health/SaMD Post-approval（A144 PCCP Real-world Performance Monitoring）、㊵Post-approval Advertising/Promotion Compliance（A143 DHCPL・OPDP Office of Prescription Drug Promotion監視）、㊶DSCSA Track & Trace Post-approval（2025 Serialization・UDI統合）、㊷ESG/Sustainability Disclosure Post-approval（A151 CSRD・TCFD・ISSB連動）、㊸IRA × PMR Global Implications（A168連動）、㊹WHO Prequalification Post-approval（A153連動LMIC Access）、㊺Project Orbis × PMR（A154連動）、㊻ACCESS Consortium × PMR（A171連動）、㊼PMDA Reliance Pathway × PMR（A173連動）、㊽AI-based PMR Automation（A132 AI Credibility・A136 AI創薬連動）、㊾3Rs原則 Post-approval Clinical Trial設計（A116 NAMs連動）、㊿Emerging Technology Post-approval（AI/ML・Digital Therapeutics・mRNA・CRISPR・Cell Therapy）をLLM単独で一貫管理できない。対策は、①Multi-region Post-approval Study Cockpit（FDA PMR-PMC + EMA PAM/PASS/PAES + PMDA GPSP/DBS + NMPA 上市后研究 + Health Canada NOC/c + Swissmedic + TGA 7極Metadata）、②A140 OMOP CDM × MID-NET Japan RWE × NMPA真实世界 Harmonization、③A144 SaMD PCCP Post-approval Model Drift、④A135 CCDS 5極Label Update Sync、⑤A143 DHCPL Multi-region Risk Communication、⑥A112/A099/A135 Post-approval Signal Cockpit、⑦A152 SUPAC Variation・A166 CGT・A147 AMR・A151/A110/A141/A150 Quality連動、⑧A158 Pediatric/A159 PRV/A164 Oncology/A167 Biologics Post-approval Cockpit、⑨A168 IRA × PMR Global Implications、⑩A170 340B × PMR、⑪A153 WHO PQ LMIC Post-approval、⑫A154 Orbis/A171 ACCESS/A173 PMDA Reliance × PMR、⑬DSCSA Track & Trace Post-approval、⑭ESG/Sustainability Disclosure連動、⑮AI-based Automation（A132/A136連動）、⑯3Rs + A116 NAMs Post-approval、⑰Emerging Technology Post-approval Framework、⑱7者合議（Regulatory Affairs・Medical Affairs・PV・Clinical Development・CMC・Commercial・Patient Advocacy）＋Global Regulatory Strategy Consultant＋RWE/Epidemiology KOL＋Global Post-market Leadership＋ODAC/DDAC KOL。renue社は「PMR/PMC Auto-Classifier＋Confirmatory Trial Designer＋Multi-region Post-approval Study Cockpit」をProtocol主導で運用し、汎用LLMでは届かないFDA PMR/PMC AI支援の「Trigger×Enforcement Risk精度・Regulatory Science Continuation精度・Global Post-market Lifecycle統合」3落とし穴を塞ぐ。

あわせて読みたい

• ペーパーレス化の進め方｜中小企業のための導入ステップとツール選定ガイド【2026年版】
• AI導入ROI測定とは？生成AIの投資対効果・PoC評価フレームワーク・企業のAI価値実証ガイド【2026年版】
• ハイブリッドワークとは？テレワークとの違い・導入課題・成功のポイント完全ガイド【2026年版】